Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.
Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi HR, Kim SB, Bear HD, McCarthy N, Gelmon KA, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Gnant M, Makris A, Burchardi N, Schwenkglenks M. Galactionova K, et al. Among authors: kelly cm. Front Oncol. 2022 Sep 5;12:886831. doi: 10.3389/fonc.2022.886831. eCollection 2022. Front Oncol. 2022. PMID: 36132153 Free PMC article.
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M, Huang-Bartelett C, Lechuga Frean MJ, Colleoni M, Werutsky G, Seiler S, Burchardi N, Nekljudova V, von Minckwitz G. Loibl S, et al. Among authors: kelly cm. J Clin Oncol. 2021 May 10;39(14):1518-1530. doi: 10.1200/JCO.20.03639. Epub 2021 Apr 1. J Clin Oncol. 2021. PMID: 33793299 Clinical Trial.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. Kalinsky K, et al. Among authors: kelly cm. N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1. N Engl J Med. 2021. PMID: 34914339 Free PMC article. Clinical Trial.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study.
García-Sáenz JA, Marmé F, Untch M, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, Martin M, Kelly CM, Reimer T, Toi M, Law E, Bhattacharyya H, Gnant M, Makris A, Seiler S, Burchardi N, Nekljudova V, Loibl S, Rugo HS. García-Sáenz JA, et al. Among authors: kelly cm. Eur J Cancer. 2024 Jan;196:113420. doi: 10.1016/j.ejca.2023.113420. Epub 2023 Nov 5. Eur J Cancer. 2024. PMID: 38000218
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.
Marmé F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, García-Sáenz JA, Kelly CM, Reimer T, Valota O, Toi M, Rugo HS, Gnant M, Makris A, Bassy M, Zhang Z, Furlanetto J, Nekljudova V, Loibl S. Marmé F, et al. Among authors: kelly cm. ESMO Open. 2024 Jun 4;9(6):103466. doi: 10.1016/j.esmoop.2024.103466. Online ahead of print. ESMO Open. 2024. PMID: 38838498 Free article.
Aromatase inhibitors in premenopausal breast cancer.
Kelly CM, Buzdar AU. Kelly CM, et al. Lancet Oncol. 2012 Apr;13(4):320-1. doi: 10.1016/S1470-2045(11)70399-0. Epub 2012 Jan 20. Lancet Oncol. 2012. PMID: 22265695 No abstract available.
First international consensus guidelines for breast cancer in young women (BCY1).
Partridge AH, Pagani O, Abulkhair O, Aebi S, Amant F, Azim HA Jr, Costa A, Delaloge S, Freilich G, Gentilini OD, Harbeck N, Kelly CM, Loibl S, Meirow D, Peccatori F, Kaufmann B, Cardoso F. Partridge AH, et al. Among authors: kelly cm. Breast. 2014 Jun;23(3):209-20. doi: 10.1016/j.breast.2014.03.011. Epub 2014 Apr 24. Breast. 2014. PMID: 24767882
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆.
Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, Hatschek T, Kelly CM, Peña-Murillo C, Yilmaz M, Donica M, Ellis P. Montemurro F, et al. Among authors: kelly cm. Ann Oncol. 2020 Oct;31(10):1350-1358. doi: 10.1016/j.annonc.2020.06.020. Epub 2020 Jul 5. Ann Oncol. 2020. PMID: 32634611 Free article. Clinical Trial.
338 results